Cancer clinical trials in the region Centre-Val de Loire
48 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3
Kidney cancer
#NCT06364631
Clear cell carcinoma
Metastatic
None
0
1 or 2
Systemic Treatment-Naive
7 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT05899608
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Metastatic
Systemic Treatment-Naive
ALK
EGFR
ROS-1
8 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Summit Therapeutics
Phase 3
Prostate cancer
#NCT06120491
Metastatic Hormone-sensitive
Other mutation
Surgery
Radiotherapy
Systemic Treatment-Naive
8 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
AstraZeneca
Phase 3
Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
PDL1 Negative (< 1%)
None
Systemic Treatment-Naive
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
11 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Amgen